Shares of Insys Therapeutics dropped about 8 percent Monday amid renewed concerns over the pharmaceutical company’s sales practices.
NBC News, citing a whistleblower, reported that Subsys — an addictive painkiller 100 times more powerful than morphine used to treat “breakthrough” cancer pain — had been prescribed to patients who shouldn’t have received it.
